Laurus Labs Limited — Capital/Financing Update 2025

Jul 25, 2025

July 25, 2025

==> picture [190 x 81] intentionally omitted <==

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / madam,

With reference to the above, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e., Friday, 25[th] July, 2025, inter-alia, have approved the investment of an amount of INR equivalent of up to EURO 5,000,000/- (Euro Five Million only) in KRKA Pharma Private Limited (“KRKA”), a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of INR equivalent of about EURO 5,000,000/- (Euro Five Million only) in KRKA. The existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs Limited shall remain the same post-investment.

The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company’s strategic growth plans and longterm business objectives.

The required details under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure-A .

The Board Meeting commenced at 02.00 p.m. and concluded at 02.55 p.m.

Please take the above information on record.

Yours faithfully,

For Laurus Labs Limited

VENKATESWAR Digitally signed by VENKATESWAR REDDY REDDY GOGIREDDY GOGIREDDY Date: 2025.07.25 15:03:49 +05'30'

G. Venkateswar Reddy

Company Secretary & Compliance Officer

Encl: A/a

==> picture [453 x 76] intentionally omitted <==

==> picture [190 x 81] intentionally omitted <==

Annexure-A

BRIEF DETAILS OF THE INVESTMENT

(Pursuant to SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024)

a) Name of the target entity, details in brief such as size, turnover etc.:

KRKA Pharma Private Limited (“KRKA”), a joint venture of the Company, incorporated under the Companies Act, 2013. The Authorised Share Capital of KRKA is INR 270,00,00,000/- divided into 27,00,00,000 equity shares of INR 10/- each and paid-up Share Capital of the Company is INR 215,00,00,000/- divided into 21,50,00,000 equity shares of INR 10/- each.

Turnover: Nil (Target entity is yet to commence its operations)

b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:

Yes. As KRKA is the joint venture of the Company having common Directors, the proposed investment in KRKA by the Company would fall within the purview of related party transaction in terms of SEBI (LODR) Regulations, 2015. The nature of interest is to the extent of investment by the Company and the transaction is being done at arms' length basis. No Promoter/ Promoter Group/ other Group Company is holding equity shares in the target entity.

c) Industry to which the entity being acquired belongs:

KRKA belongs to the pharmaceutical industry.

d) Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):

KRKA is already a joint venture company of our Company and further investment by the Company and by KRKA d.d., Novo mesto, Slovenia (“co-venturer”) will enable KRKA to meet the cost of setting up of a manufacturing facility.

e) Brief details of any governmental or regulatory approvals required for the acquisition:

No approvals required.

f) Indicative time period for completion of the acquisition:

The investment by the Company is expected to be completed on or before 31.12.2025.

g) Consideration - whether cash consideration or share swap or any other form and details of the same:

Cash consideration by way of subscribing to Equity Shares which shall be issued by KRKA to the Company.

h) Cost of acquisition and/or the price at which the shares are acquired:

Cost of acquisition: An amount of INR equivalent of Up to EURO 5,000,000/- (Euro Five Million only)

Price at which the shares are acquired: INR 10/- each per equity share (Face Value)

==> picture [453 x 76] intentionally omitted <==

==> picture [190 x 81] intentionally omitted <==

i) Percentage of shareholding / control acquired and / or number of shares acquired:

The current percentage of shareholding in the target entity is 49% and after this investment by our Company and the co-venturer, the percentage of shareholding by the Company shall remain same at 49%.

• j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):

Brief background: KRKA was incorporated in 2024 and is yet to commence its business operations.

Date of Incorporation: April 12, 2024

Country in which the acquired entity has presence: N.A.

Turnover for the last three years: Nil for 2024-25.

==> picture [453 x 76] intentionally omitted <==

---